Ulcerative Colitis

CAT Product Candidates CAT-354 is a fully human anti-IL13 monoclonal antibody being developed by CAT, initially as a treatment for severe asthma.

Following the completion in 2005 of a Phase I clinical trial, CAT has recently received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to commence a repeat-dose safety study of CAT-354 in patients with mild/moderate asthma.

The trial, which will take place in the UK, will commence in the first quarter of calendar year 2006 and will study safety, tolerability and pharmacokinetics.

The development of CAT-3888 and CAT-8015, immunotoxins which are potential treatments for a number of B-cell malignancies, continues as planned.

GC-1008 is a pan-specific fully human anti-TGF(beta) monoclonal antibody being developed by CAT and Genzyme.

The companies anticipate that an IND application for a Phase I clinical trial in oncology indications will be filed in the first quarter of calendar year 2006.

The strategic alliance with AstraZeneca continues its excellent progress, with six active discovery programmes.

Other Licensed Product Candidates ABT-874 is a fully human anti-IL-12 monoclonal antibody, isolated and optimised by CAT in collaboration with Abbott and licensed to Abbott.

Abbott continues to develop ABT...

Read more...